Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Discover how a Provisional Patent Application protects your invention with the "patent pending" label and learn about its ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Edwards Lifesciences (EW) newly projected 2026 adjusted EPS guidance of $2.80-$2.95 includes to consensus figure of $2.86. The maker of products to treat advanced cardiovascular diseases also sees ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Learn what unadjusted basis is, how it works, and see examples of its application in asset valuation and tax calculations to aid in your financial decision-making.